DATED 5 October 2023 GLAXO GROUP LIMITED and PFIZER INC. and GSK (NO.1) SCOTTISH LIMITED PARTNERSHIP and GSK (NO.2) SCOTTISH LIMITED PARTNERSHIP and GSK (NO.3) SCOTTISH LIMITED PARTNERSHIP and MERRILL LYNCH INTERNATIONAL and CITIGROUP GLOBAL MARKETS...GSK PLC • October 10th, 2023 • Pharmaceutical preparations
TERMS OF SALESecondary Block Trade Agreement • October 10th, 2023 • GSK PLC • Pharmaceutical preparations
Further to the provisions of the SECONDARY BLOCK TRADE AGREEMENT DATED 5 October 2023 between GSK (No.1) Scottish Limited Partnership (“SLP 1”), GSK (No.2) Scottish Limited Partnership (“SLP 2”) and GSK (No.3) Scottish Limited Partnership (“SLP 3”), Glaxo Group Limited and Merrill Lynch International and Citigroup Global Markets Limited (the “Agreement”), the following terms of sale are agreed:
SECONDARY BLOCK TRADE AGREEMENT, made on 5 October 2023 BETWEENSecondary Block Trade Agreement • October 10th, 2023 • GSK PLC • Pharmaceutical preparations
GSK (No.1) Scottish Limited Partnership (“SLP1”), a private fund limited partnership registered in Scotland with registration number SL035527 and whose principal place of business is at 50 Lothian Road, Festival Square, Edinburgh, EH3 9WJ;
